申请人:ONO PHARMACEUTICAL CO., LTD.
公开号:EP2592066A1
公开(公告)日:2013-05-15
The present invention relates to a compound represented by the formula (I), a salt thereof, an N-oxide form thereof, a solvate thereof, or a prodrug thereof, and a medicament containing the same. The compound represented by the formula (I) has an ability to bind to an S1P receptor (particularly, EDG-1, EDG-6, and/or EDG-8) and is useful for preventing and/or treating for rejection to transplantation, graft-versus-host disease, autoimmune diseases, allergic diseases, neurodegenerating diseases, and the like.
wherein all symbols are described in the specification.
本发明涉及一种由式(I)代表的化合物、其盐、其N-氧化物形式、其溶液或其原药,以及含有该化合物的药物。式(I)代表的化合物具有与S1P受体(特别是EDG-1、EDG-6和/或EDG-8)结合的能力,可用于预防和/或治疗移植排斥反应、移植物抗宿主疾病、自身免疫性疾病、过敏性疾病、神经变性疾病等。
其中所有符号在说明书中均有描述。